University of Chicago Medicine will soon begin testing another potential COVID-19 vaccine, and is looking for up to 2,000 people to enroll in the phase three clinical trial.
The trial is designed to evaluate the safety and efficacy of a single dose of a vaccine produced by Janssen Pharmaceutical Companies of Johnson & Johnson. The trial began enrolling 60,000 adults across the world in September.
It’s one of a handful of potential vaccines now in advanced clinical trials in the U.S.
The international trial of the Janssen vaccine was temporarily paused in October after one participant developed an unexplained illness.
“Such pauses are not uncommon in vaccine trials, and late last week the FDA approved the resumption of the trial after an independent committee found the vaccine did not cause the illness,” University of Chicago Medicine leaders wrote in an email sent Monday to faculty, staff and students.
This is the second COVID-19 vaccine trial University of Chicago Medicine has offered. Since mid-September, the system has also been enrolling subjects in the Moderna COVE trial.
To participate in the Janssen trial and future research, people can join UChicago Medicine’s registry.
Other large hospital systems in Chicago are also participating in COVID-19 vaccine trials, including the University of Illinois at Chicago, which is part of the Moderna trial, and Northwestern Medicine, which is part of a trial of the AstraZeneca Oxford vaccine.
©2020 the Chicago Tribune
Visit the Chicago Tribune at www.chicagotribune.com
Distributed by Tribune Content Agency, LLC.